Literature DB >> 27782364

Survival at 2 years among liver cirrhotic patients is influenced by left atrial volume and left ventricular mass.

Manuela Merli1, Concetta Torromeo2, Michela Giusto1, Gianna Iacovone1, Oliviero Riggio1, Paolo E Puddu2.   

Abstract

BACKGROUND & AIMS: Cirrhotic cardiomyopathy (CC) may interact with the clinical course of cirrhosis and can be implicated in the development of several complications in advanced liver disease. The best and easiest parameters which should define a condition of reduced cardiac reserve in cirrhosis are still controversial. This study was aimed at selecting the cardiac parameters, derived by Doppler echocardiography, predictive of survival during follow-up.
METHODS: This study included cirrhotic patients without cardiovascular or pulmonary diseases. Patients were studied in stable conditions. Doppler echocardiography was used to select parameters associated with survival. Among the others, left atrial volume (LAVi) and left ventricular mass indexed to body surface area (LVMi) were evaluated. A comparison was performed with the parameters presently applied for the definition of CC according to the Montreal criteria.
RESULTS: Ninety cirrhotic patients have been included (males 66%, alcohol origin 31%, post-viral 54%, Child-Pugh A 53%, B 29% and C 18%). Patients were followed up for at least 24 months. Twenty-six patients had a diagnosis of CC according to the Montreal criteria. During follow-up, 24 patients died. Overall mortality was 26.7%. Patients presenting higher LAVi and lower LVMi were those at higher risk to die (P=.04 and P=.007 respectively). No difference in survival was seen in patients with a diagnosis of CC.
CONCLUSIONS: An increased LAVi and a decreased LVMi were able to differentiate among patients with a lower survival at 2 years. These parameters need to be considered for prognostic evaluation in cirrhotics.
© 2016 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  cirrhosis; cirrhotic cardiomyopathy; prognosis

Mesh:

Year:  2016        PMID: 27782364     DOI: 10.1111/liv.13287

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  6 in total

1.  Redefining Cirrhotic Cardiomyopathy for the Modern Era.

Authors:  Manhal Izzy; Lisa B VanWagner; Grace Lin; Mario Altieri; James Y Findlay; Jae K Oh; Kymberly D Watt; Samuel S Lee
Journal:  Hepatology       Date:  2019-10-11       Impact factor: 17.425

2.  Blunted cardiovascular effects of beta-blockers in patients with cirrhosis: Relation to severity?

Authors:  Puria Nabilou; Karen Vagner Danielsen; Nina Kimer; Jens Dahlgaard Hove; Flemming Bendtsen; Søren Møller
Journal:  PLoS One       Date:  2022-06-28       Impact factor: 3.752

3.  Diagnosis and Management of Cirrhotic Cardiomyopathy.

Authors:  Harpreet Kaur; Madhumita Premkumar
Journal:  J Clin Exp Hepatol       Date:  2021-08-21

Review 4.  Cardiac Imaging in Liver Transplantation Candidates: Current Knowledge and Future Perspectives.

Authors:  Yannis Dimitroglou; Constantina Aggeli; Alexandra Alexopoulou; Sophie Mavrogeni; Dimitris Tousoulis
Journal:  J Clin Med       Date:  2019-12-03       Impact factor: 4.241

5.  Prevalence and prognostic value of cirrhotic cardiomyopathy as defined according to the proposed new classification.

Authors:  Maurizio Cesari; Anna Chiara Frigo; Salvatore Piano; Paolo Angeli
Journal:  Clin Exp Hepatol       Date:  2021-08-23

6.  Early echocardiographic signs of diastolic dysfunction predict acute kidney injury in cirrhotic patients.

Authors:  Pei-Shan Wu; Ying-Wen Wang; Cheng-Chun Tai; Yun-Cheng Hsieh; Pei-Chang Lee; Chin-Chou Huang; Yi-Hsiang Huang; Ming-Chih Hou; Han-Chieh Lin; Kuei-Chuan Lee
Journal:  J Chin Med Assoc       Date:  2020-11       Impact factor: 3.396

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.